Caldecrin proform requires trypsin activation for the acquisition of serum calcium-decreasing activity.
Proform serum calcium-decreasing factor (procaldecrin) was purified from porcine pancreas acetone powder. Procaldecrin showed chymotrypsin activity after trypsin treatment in a time- and dose-dependent manner. Procaldecrin did not possess serum calcium-decreasing activity but acquired serum calcium-decreasing activity as well as protease activity after trypsin treatment. However, PMSF treatment after activation of procaldecrin by trypsin did not affect the serum calcium-decreasing activity, even though protease activity was nullified by treatment with PMSF. These findings suggest that the serum calcium-decreasing activity acquired by procaldecrin requires conformational change caused by trypsin treatment.
Tomomura
A
A
Department of Biochemistry, Faculty of Medicine, Kagoshima University, Japan.
Fukushige
T
T
Tomomura
M
M
Noikura
T
T
Nishii
Y
Y
Saheki
T
T
D000595:Amino Acid Sequence; D000818:Animals; D002118:Calcium / Q000097:blood*; D004789:Enzyme Activation; D004792:Enzyme Precursors / Q000378:metabolism*; D008969:Molecular Sequence Data; D012697:Serine Endopeptidases / Q000378:metabolism*; D013552:Swine; D014357:Trypsin / Q000378:metabolism*
D004792:Enzyme Precursors; D012697:Serine Endopeptidases; C074385:caldecrin; D014357:Trypsin; D002118:Calcium